Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

@article{Liossis2006MycophenolateMA,
  title={Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.},
  author={Stamatis-Nick Liossis and A. Bounas and Andrew P. Andonopoulos},
  journal={Rheumatology},
  year={2006},
  volume={45 8},
  pages={1005-8}
}
OBJECTIVE To find an effective, safe immunosuppressive regimen as an alternative to cyclophosphamide (Cy) for the treatment of clinically evident diffuse scleroderma (dSSc)-associated alveolitis of recent onset. METHODS Five consecutive patients with dSSc and recent-onset alveolitis were enrolled and treated with mycophenolate mofetil (MMF) and small (< or =10 mg/day) doses of predinisolone in this open-label trial. One patient with long-standing fibrosing alveolitis was later added to our… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…